Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
Summary: Intra-Cellular seeks FDA approval for Caplyta to treat major depressive disorder – an expansion that could generate an additional $1B in revenue, with Jefferies analysts noting the stock remains undervalued.
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
Summary: COUR and Genentech (Roche) have partnered to utilize COUR’s antigen-specific immune tolerance platform for developing therapies targeting an undisclosed autoimmune disease.
Novartis wagers billions of dollars on PTC Huntington’s drug
Summary: At the center of a new licensing deal is an experimental medicine currently being tested in a roughly 250-person study that should produce results next year.
Diabetes advocacy group discourages use of compounded GLP-1 drugs
Summary: The American Diabetes Association recommended doctors prescribe alternative FDA-approved drugs as Wegovy and Zepbound remain difficult to reliably obtain.
Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M
Summary: Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven platform to discover and develop therapeutic miniproteins for two undisclosed targets.
